
Quest Diagnostics (DGX) Stock Forecast & Price Target
Quest Diagnostics (DGX) Analyst Ratings
Bulls say
Quest Diagnostics is strategically positioned in the healthcare industry through its national network of patient service centers and partnerships, as well as its advanced diagnostic solutions segment. Fiscal year 2026 guidance being moved higher, strong core demand trends, and potential for share gains and M&A growth contribute to a positive outlook, despite a premium stock valuation and potential headwinds such as weather impacts and cost investment for Project Nova. Overall, this company has solid financials and maintains a strong position in the market, suggesting a positive outlook for the future.
Bears say
Quest Diagnostics is facing challenges in its core clinical testing business due to growing competition and pricing pressures. While the company is seeing strong growth in advanced diagnostic areas like Alzheimer's testing, it is not enough to offset the declining revenue in its traditional testing segments. Additionally, Quest's attempts to cut costs and improve margins through the use of AI may not be enough to sustain long-term growth and profitability in an increasingly competitive market.
This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Quest Diagnostics (DGX) Analyst Forecast & Price Prediction
Start investing in Quest Diagnostics (DGX)
Order type
Buy in
Order amount
Est. shares
0 shares